Foghorn Therapeutics Inc.
FHTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $259,125 | $270,735 | $265,353 | $850,104 |
| - Cash | $55,454 | $80,336 | $345,798 | $101,136 |
| + Debt | $37,131 | $45,073 | $51,507 | $58,332 |
| Enterprise Value | $240,802 | $235,472 | -$28,938 | $807,300 |
| Revenue | $22,602 | $34,155 | $19,228 | $1,319 |
| % Growth | -33.8% | 77.6% | 1,357.8% | – |
| Gross Profit | $22,602 | $34,155 | $19,228 | $1,319 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$97,165 | -$104,455 | -$113,816 | -$96,187 |
| % Margin | -429.9% | -305.8% | -591.9% | -7,292.4% |
| Net Income | -$86,620 | -$98,426 | -$108,882 | -$101,320 |
| % Margin | -383.2% | -288.2% | -566.3% | -7,681.6% |
| EPS Diluted | -1.58 | -2.34 | -2.62 | -2.78 |
| % Growth | 32.5% | 10.7% | 5.8% | – |
| Operating Cash Flow | -$100,406 | -$118,106 | $193,612 | -$50,250 |
| Capital Expenditures | -$906 | -$1,224 | -$1,210 | -$3,313 |
| Free Cash Flow | -$101,312 | -$119,330 | $192,402 | -$53,563 |